Study type: Human research · Status: Verified against declared source

Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.

Frontiers in immunology · 2021

Study scale: Tα1 is an endogenous polypeptide hormone secreted by thymic epithelial cells (12).

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear.

Methods

This was a multicenter cohort study conducted at five tertiary hospitals (in the Hubei province of China) that were designated by the Chinese government as COVID-19 treatment sites: including Union Jiangbei Hospital, Wuhan No.

Scale or participants

Tα1 is an endogenous polypeptide hormone secreted by thymic epithelial cells (12).

Key findings

All crude outcomes, including non-recovery rate (65/306 vs.

Limitations and uncertainty

Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.